UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 156

Sortiert nach

Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome

Cancer, 2023-06, Vol.129 (11), p.1704-1713

2023

Volltextzugriff (PDF)

Severe Peripheral Arterial Disease During Nilotinib Therapy

JNCI : Journal of the National Cancer Institute, 2011-09, Vol.103 (17), p.1347-1348

2011

Volltextzugriff (PDF)

Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy

Cancer, 2024-04, Vol.130 (8), p.1270-1280

2024

Volltextzugriff (PDF)

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

British journal of haematology, 2021-04, Vol.193 (2), p.356-368

2021

Volltextzugriff (PDF)

Back to the future: Treatment‐free remission and pregnancy in chronic myeloid leukemia

European journal of haematology, 2019-02, Vol.102 (2), p.197-199

2019

Volltextzugriff (PDF)

Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group

Annals of hematology, 2022-06, Vol.101 (6), p.1275-1282

2022

Volltextzugriff (PDF)

Successful Decitabine Treatment in Unfit, Elderly Patients with Acute Myeloid Leukemia following Chronic Myeloproliferative Neoplasm

Acta haematologica, 2018-01, Vol.140 (4), p.231-233

2018

Volltextzugriff (PDF)

Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR)

Cancers, 2023-08, Vol.15 (16), p.4112

2023

Volltextzugriff (PDF)

SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection

Mediterranean journal of hematology and infectious diseases, 2020, Vol.12 (1), p.e2020031-e2020031

2020

Volltextzugriff (PDF)

Tyrosine kinase inhibitors and pregnancy

Mediterranean journal of hematology and infectious diseases, 2014-01, Vol.6 (1), p.e2014028-e2014028

2014

Volltextzugriff (PDF)

Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases, Nilotinib Placental Transfer

Journal of clinical medicine, 2022-03, Vol.11 (7), p.1801

2022

Volltextzugriff (PDF)

The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population

Cancer medicine (Malden, MA), 2021-09, Vol.10 (18), p.6310-6316

2021

Volltextzugriff (PDF)

Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients

Oncotarget, 2016-11, Vol.7 (44), p.72311-72321

2016

Volltextzugriff (PDF)

Treatment-Free Remission in Chronic Myeloid Leukemia: Lights and Shadows

Hematology reports, 2020-09, Vol.12 (11), p.8950-8950

2020

Volltextzugriff (PDF)

NPM1 Mutated, BCR-ABL1 Positive Myeloid Neoplasms: Review of the Literature

Mediterranean journal of hematology and infectious diseases, 2020-11, Vol.12 (1), p.e2020083-e2020083

2020

Volltextzugriff (PDF)

Characterization of Ph‐negative abnormal clones emerging during imatinib therapy

Cancer, 2007-06, Vol.109 (12), p.2466-2472

2007

Volltextzugriff (PDF)

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

Blood cancer journal (New York), 2023-05, Vol.13 (1), p.65-65, Article 65

2023

Volltextzugriff (PDF)

Pyrrolo[1,2‐b][1,2,5]benzothiadiazepines (PBTDs) exert their anti‐proliferative activity by interfering with Akt–mTOR signaling and bax:bcl‐2 ratio modulation in cells from chronic myeloid leukemic patients

Cancer science, 2010-04, Vol.101 (4), p.991-1000

2010

Volltextzugriff (PDF)

Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients

Journal of hematology and oncology, 2016-07, Vol.9 (1), p.63-63, Article 63

2016

Volltextzugriff (PDF)

Impact on mental health, disease management, and socioeconomic modifications in hematological patients during the COVID-19 pandemic in Italy

Therapeutic advances in hematology, 2023-01, Vol.14, p.20406207231190683-20406207231190683

2023

Volltextzugriff (PDF)

1 – 25 von 156

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(131)
Mit Volltextzugriff
(150)

Publikationsform

Artikel
(148)
Berichte
(8)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(73)
Science & Technology
(73)
Hematology
(47)
Humans
(47)
Oncology
(43)
Female
(33)
Male
(28)
Aged
(22)
Chronic Myeloid Leukemia
(22)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(20)
Adult
(18)
Middle Aged
(18)
Aged, 80 And Over
(17)
Leukemia
(17)
Treatment Outcome
(14)
Retrospective Studies
(13)
Medicine
(11)
Medicine & Public Health
(11)
Myelofibrosis
(11)
Ruxolitinib
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome

Severe Peripheral Arterial Disease During Nilotinib Therapy

Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

Back to the future: Treatment‐free remission and pregnancy in chronic myeloid leukemia

Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome

Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic‐phase myelofibrosis

Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group

Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

Successful Decitabine Treatment in Unfit, Elderly Patients with Acute Myeloid Leukemia following Chronic Myeloproliferative Neoplasm

Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR)

SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection

Tyrosine kinase inhibitors and pregnancy

Favorable outcome of chronic myeloid leukemia co‐expressing e13a2 and e14a2 transcripts, treated with nilotinib

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis

Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases, Nilotinib Placental Transfer

The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population

Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients

Treatment-Free Remission in Chronic Myeloid Leukemia: Lights and Shadows

NPM1 Mutated, BCR-ABL1 Positive Myeloid Neoplasms: Review of the Literature

Characterization of Ph‐negative abnormal clones emerging during imatinib therapy

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

Pyrrolo[1,2‐b][1,2,5]benzothiadiazepines (PBTDs) exert their anti‐proliferative activity by interfering with Akt–mTOR signaling and bax:bcl‐2 ratio modulation in cells from chronic myeloid leukemic patients

Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients

Impact on mental health, disease management, and socioeconomic modifications in hematological patients during the COVID-19 pandemic in Italy

Suchergebnisse filtern